Target markets Spectradyne’s MRPS-based particle analysis serves both life science applications (extracellular vesicle research, gene therapy, nanomedicine, vaccine development, liposomes, lipid nanoparticles) and industrial materials (polymeric nanoparticles, CMP slurry, paints, inks, foods, coatings). This dual focus presents sales opportunities across research labs, biotech startups, contract research organizations, pharmaceutical developers, and materials manufacturers.

Small sample value The technology requires only 3 microliters for total analysis and can handle complex samples like plasma and cell culture media directly. This efficiency is attractive to budget-conscious labs with limited sample availability or precious specimens, enabling high-value analyses with minimal material use.

Competitive edge MRPS provides a more accurate alternative to light scattering methods for particle analysis, positioning Spectradyne as a premium solution for precise counting and sizing at 50 nm to 10 μm. Emphasize reliability and one-by-one electrical counting to differentiate from optical competitors in customer conversations.

Trial-driven growth The company offers free measurements of a few samples to demonstrate capabilities, which is a low-friction entry point for engagements with researchers and procurement teams. This trial approach can be scaled into formal pilots or licensing discussions with potential enterprise customers.

Growth channels With a small team and early-stage revenue, partnerships with contract research organizations, academic collaborations, and distributors in biotech and materials industries could accelerate market penetration. Leverage the current funding and highlight rapid deployment advantages to attract strategic investors or channel partners.